Gensight Biologics SA
PAR:SIGHT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Daiwa Securities Living Investment Corp
TSE:8986
|
JP |
Gensight Biologics SA
Stock-Based Compensation
Gensight Biologics SA
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Stock-Based Compensation
€604k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Stock-Based Compensation
€552k
|
CAGR 3-Years
11%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Stock-Based Compensation
$4.1m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Stock-Based Compensation?
Stock-Based Compensation
604k
EUR
Based on the financial report for Jun 30, 2025, Gensight Biologics SA's Stock-Based Compensation amounts to 604k EUR.
What is Gensight Biologics SA's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
-23%
Over the last year, the Stock-Based Compensation growth was 44%.
